Skip to main content
Michael Menden
Helmholtz Munich | Michael Haggenmueller

Dr. Michael P. Menden

Junior Group Leader

“Our research focus is studying multi-omics landscapes of complex diseases, understanding their mechanisms and suggesting novel treatment strategies based on machine learning and biostatistics.”

 

“Our research focus is studying multi-omics landscapes of complex diseases, understanding their mechanisms and suggesting novel treatment strategies based on machine learning and biostatistics.”

 

 

Translational Computational Pharmacogenomics

The mission of our research group is to develop biostatistical and machine learning frameworks applied to biomedical data, to retrieve insights in the aetiology of complex diseases and identify patient stratifications. For this, we explore deep molecular characterised biomedical datasets, environmental factors, and tailor our models depending on disease specific knowledge gained through literature and data driven analyses, thus empowering the next generation of precision medicine.

More

Dr. Michael P. Menden is a Junior Group Leader at the Computational Health Center, Helmholtz Munich since 2019. He is leading the Menden Lab and is Head of the DZD Computational Biology Unit. Dr. Menden became an ERC Starting Grant Laureate in 2020, and was awarded the Rising Star in Drug Discovery Award by the University of Cardiff in 2022. Previously, Dr. Menden worked as Senior Scientist in Oncology Bioinformatics, AstraZeneca, UK. He was a PhD student and postdoctoral fellow at EMBL-EBI, UK. His PhD was awarded in Computational Biology by the University of Cambridge, UK in 2016. In 2017, Dr. Menden was appointed an Honorary Lecturer position at the University of Sheffield, UK. Since 2019, Dr. Menden also became a lecturer in the Technical University of Munich (TUM) and Ludwig Maximilian University (LMU).

Computational Biomedicine

drug discoveryBig Dataprecision medicinedrug target identificationdrug repurposingmachine learningbiostatisticsdrug high-throughput screens

Professional Background

2019 - present

Principal Investigator, Computational Biomedicine Group

Institute of Computational Biology (ICB), Helmholtz Munich, Germany

2019 - present

Head of DZD Computational Biology Unit

German Center for Diabetes Research, Helmholtz Munich, Germany

2016-2019

Senior Scientist in Oncology Bioinformatics

Innovative Medicines and Early Development (IMED) Oncology, AstraZeneca, UK

2016 - 2016

Short-Term Postdoctoral Fellow in Saez-Rodriguez Lab

University Hospital Aachen & RWTH Aachen, Germany

2011-2016

PhD student in Saez-Rodriguez Lab

EMBL-EBI, UK

2009

Visiting Researcher in Sorger Lab

Department of Systems Biology, Harvard Medical School (HMS), USA

Honors and Awards

  • 2022
    McGuigan Drug Discovery Rising Star Prize, Cardiff University, UK

  • 2020
    ERC Starting Grant

  • 2018
    AstraZeneca Award for driving successful external oncology collaborations, UK

  • 2017
    AstraZeneca Leadership Team Recognition Award, UK

  • 2013
    Sage Bionetworks Young Investigator Award, Sage Bionetworks, USA

  • 2011
    EMBL-EBI Pre-Doctoral Fellowship, UK

  • 2008
    ERASMUS Scholarship, DAAD, Germany

Gold Star Awards Luxury Background
suppa - stock.adobe.com

Publications

Read more

2024 Scientific Article in The journal of allergy and clinical immunology

Schärli, S. ; Luther, F. ; Di Domizio, J. ; Hillig, C. ; Radonjic-Hoesli, S. ; Thormann, K. ; Simon, D. ; Møller Rønnstad, A.T. ; Ruge, I.F. ; Fritz, B.G. ; Bjarnsholt, T. ; Vallone, A. ; Kezic, S. ; Menden, M.P. ; Roesner, L.M. ; Werfel, T. ; Thyssen, J.P. ; Eyerich, S. ; Gilliet, M. ; Bertschi, N.L. ; Schlapbach, C.

IL-9 sensitizes human Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis.

Networks and Affiliations

Logo LMU - Ludwig-Maximilians-Universität München

LMU

Biology Faculty